• Risk/Outcomes Contracting Has Finally Arrived

    Feature Articles by on February 24th, 2017

    In our organization’s payer market research, we generally find pharmacy and medical directors respond to proposed risk- or outcomes-based contracting with muted interest. The reasons often include cost of contract management, lack of internal staff and infrastructure to extract and report the data, and inconsistent data availability across their membership. Among insurers and networks, electronic […]

  • The Promise and Threat of Biosimilars

    Panorama by on October 31st, 2016

    The number of biologics available in the U.S. has grown every year for the last 17 years, making biologics a large part of the pharmaceutical marketplace.1 By 2020, they are expected to account for one-third of all global pharmaceutical revenue. The therapeutic areas that are most affected by biologics include diseases for which there are […]

  • The Value Crisis in Pharma

    Panorama by on August 30th, 2016

    The core of pharmaceutical marketing has expanded from efficacy and safety to include value. Often, value is conflated with price, especially by payer organizations. Value encompasses more than just prices: It also includes the measurable health improvement that the patient receives. Value can be assessed through pharmacoeconomics, using metrics like quality-adjusted life years that allow […]

  • Winners & Losers: Assessing the Impact of the ACA

    Feature Articles by and on September 1st, 2012

    Now that the Supreme Court has upheld the Affordable Care Act, which market segments of the pharmaceutical community stand to benefit, be adversely hit, or not be affected at all? Two pharma industry veterans offer some insight and predictions. As the dust settles from the June Supreme Court ruling upholding the constitutionality of most of […]

Back to top